Companies › Voyager Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Neurology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VY7523 Monoclonal antibody targeting pathological tau | MAPT | Phase 1 | Alzheimer's Disease (AD) | May 2027 |
| VY1706 AAV9-delivered progranulin (GRN) gene therapy | GRN | Phase 1 | Alzheimer s Disease | Apr 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06874621 | VY7523 | Phase 1 | Alzheimer's Disease (AD) | Neurology | May 2027 |
| NCT07764146 | VY1706 | Phase 1 | Alzheimer s Disease | Neurology | Apr 2029 |
Cash and short-term investments of $132m on 2026-09-30; operating cash outflow about $106m a year; runway about 15 months at that burn, to Dec 2027
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Eli Radiopharma Bristol-Myers Squibb Roche Amyloid Solution Arrowhead Pharmaceuticals Nuravax Oligomerix UCB Biopharma SRL Prevail Therapeutics AviadoBio
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.